of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filin…

CFO — Sriram Ryali: The CFO's employment is set to terminate upon the execution of a strategic alternative, constituting a loss of a senior executive.

Other Events. On October 2, 2026, the Board approved initiating a process to evaluate strategic alternatives to maximize stockholder value, including, but not limited to, a merger, acquisition, business combination, or other strategic transactions involving the Company and/or its assets, and approved a planned discontinuation of further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymp…

Costs Associated with Exit or Disposal Activities. On October 2, 2026, the Board of Directors (the “Board”) of Caribou Biosciences, Inc. (the “Company”) approved a restructuring of the Company’s operations (the “Restructuring”) as the Company conducts a process to explore strategic alternatives to maximize stockholder value, including the planned discontinuation of clinical trials and further development activities for the Company’s allogeneic CAR-T cell therapy programs, vispacabtagene reged…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filin…

Other Events. On June 11, 2026 , the Company announced long-term follow-up data from its ANTLER phase 1 clinical trial that evaluated vispa-cel, an off-the-shelf CD19-targeted CAR-T cell therapy product candidate, in patients with r/r B-NHL. The Company also announced longer follow-up data from the dose escalation portion of its ongoing CaMMouflage phase 1 clinical trial evaluating CB-011, an off-the-shelf BCMA-targeted CAR-T cell therapy product candidate, in patients with r/r MM. The Compan…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such fili…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such fili…

of this Form 8-K is hereby incorporated by reference herein. Forward-Looking Statements The disclosure in this Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of the Company. These forward-looking statements are subject to a number of known and unknown risks, assumptions, uncertainties, and other factors that may cause the actual results, levels of activity, perf…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such fili…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such fili…

Results of Operations and Financial Condition. On April 24, 2025, Caribou Biosciences, Inc. (the “Company” or “Caribou”) issued a press release (the “Press Release”) announcing (i) its strategic pipeline prioritization with workforce and cost reduction initiatives and (ii) that, on a preliminary unaudited basis, it expects to report that it had $212.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025. This estimate of cash, cash equivalents, and marketable secu…

Other Events. On April 24, 2025, the Company announced that initial data from the ANTLER phase 1 clinical trial of CB-010 in a 20-patient confirmatory cohort using the Company’s partial human leukocyte antigen matching strategy in second-line (“2L”) large B cell lymphoma (“LBCL”) patients, and data from a proof of concept cohort of CB-010 in up to 10 LBCL patients who have relapsed following any prior CD19-targeted therapy, is now planned to be presented in the second half of 2025. At that ti…

Costs Associated with Exit or Disposal Activities. On April 24, 2025, the Company issued the Press Release announcing its strategic pipeline prioritization with workforce and cost reduction initiatives to focus resources on its lead oncology programs CB-010, an allogeneic anti-CD19 CAR-T cell therapy being evaluated in its ANTLER phase 1 clinical trial in patients with B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy being evaluated in its CaMMouflage phase…

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any…

The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. Forward-looking statements This Current Report contain…

Chief Financial Officer — Sriram Ryali: The company appointed a new Chief Financial Officer from an external candidate.

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such fili…

Chief Financial Officer — Jason O'Byrne: The CFO resigned and was replaced by an interim officer.

Chief Financial Officer — Jason O’Byrne: Jason O'Byrne resigned to pursue another opportunity.

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such fili…

Costs Associated with Exit or Disposal Activities. On July 16, 2024, the Company discontinued preclinical research activities associated with its allogeneic CAR-NK platform and reduced its workforce by 21 positions, or approximately 12%. The Company is undertaking this reduction to extend its cash runway and focus resources on its allogeneic CAR-T cell therapy platform and on rapidly advancing four oncology and autoimmune disease clinical programs through multiple milestones expected in 2024…

Results of Operations and Financial Condition. On July 16, 2024, Caribou Biosciences, Inc. (the “Company” or “Caribou”) reported in

of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any…